3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 2/3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Thoracic
1
Dermatologic
1
CNS
1
Conditions
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Lymphoproliferative Disorders
1
Hematologic Neoplasms
1
Glioma
1
Brain Neoplasms
1
Interventions
Temozolomide
11
Lomustine
6
Radiotherapy
4
Magnetic Resonance Spectroscopy
3
Etoposide
3
Carboplatin
3
Bevacizumab
3
vocimagene amiretrorepvec
2
Vincristine
2
Radiation
2
Gefitinib
2
veliparib
1
trofosfamide
1
trametinib
1
tozuleristide
1
tinostamustine
1
regorafenib
1
omburtamab I-131
1
entrectinib
1
dabrafenib
1
cobimetinib
1
carbon-11 acetate
1
capmatinib
1
antisecretory factor
1
alectinib
1
Vorinostat
1
Vemurafenib
1
Thiotepa
1
Sunitinib
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
entrectinib
×
CNS
×
Clear all
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled